Document Detail


Iron polymaltose versus ferrous gluconate in the prevention of iron deficiency anemia of infancy.
MedLine Citation:
PMID:  20930652     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We prospectively compared the efficacy and safety of iron deficiency anemia prophylaxis with iron gluconate (IG) or iron polymaltose complex (IPC) in healthy infants attending a community pediatric center. Participants were randomly assigned to receive one of the test drugs from age 4 to 6 months to age 12 months. Parents/guardians were given extensive information on iron-rich diets and anemia prevention. Main outcome measures were blood levels of hemoglobin, hematocrit, mean corpuscular volume, red blood cell distribution width, and serum iron, ferritin, and transferrin, in addition to adverse effects. One hundred five children completed the study: 53 in the IG group and 52 in the IPC group Mean hemoglobin levels at study end were significantly higher in the IG group (12.04±0.09 g/dL vs. 11.68±0.11, P<0.014). A hemoglobin level <11 g/dL was detected in 3 infants of the IG group, and in 10 infants of the IPC group (P<0.04). Adverse effects (spitting, vomiting, diarrhea, constipation, discolored teeth) were significantly more common in the IG group (47% vs. 25%, P>0.025). In conclusion, both oral IG and IPC prevent iron deficiency anemia in infants. Iron gluconate seems to be more effective but less tolerable.
Authors:
Lutfi Jaber; Shmuel Rigler; Ahmad Taya; Fadel Tebi; Mohamad Baloum; Isaac Yaniv; Mohamad Haj Yehia; Hanna Tamary
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  32     ISSN:  1536-3678     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-27     Completed Date:  2010-11-16     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  585-8     Citation Subset:  IM    
Affiliation:
Neurology Clinic, Schneider Children's Medical Center of Israel, Petach Tikva, Israel. jabe@bezeqint.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Iron-Deficiency / metabolism,  prevention & control*
Erythrocyte Indices
Female
Ferric Compounds / administration & dosage*,  adverse effects
Ferritins / blood
Ferrous Compounds / administration & dosage*,  adverse effects
Hematinics / administration & dosage*,  adverse effects
Hematocrit
Hemoglobins / metabolism
Humans
Infant
Infant, Newborn
Iron / blood
Male
Prospective Studies
Transferrin / metabolism
Chemical
Reg. No./Substance:
0/Ferric Compounds; 0/Ferrous Compounds; 0/Hematinics; 0/Hemoglobins; 11096-37-0/Transferrin; 18829-42-0/ferrous gluconate; 7439-89-6/Iron; 79173-09-4/teferrol; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth in children with acute lymphoblastic leukemia during treatment.
Next Document:  Gamma knife surgery of vestibular schwannomas: volumetric dosimetry correlations to hearing loss sug...